These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17012909)

  • 1. Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli.
    Zhou Z; Todd CW; Wohlhueter RM; Price A; Xiao L; Schnake P; Bonner PC; Martin AM; Goldman IF; De La Vega P; Udhayakumar V; Lal AA
    Hum Vaccin; 2006; 2(1):14-23. PubMed ID: 17012909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses of mice with different genetic backgrounds to improved multiepitope, multitarget malaria vaccine candidate antigen FALVAC-1A.
    Kaba SA; Price A; Zhou Z; Sundaram V; Schnake P; Goldman IF; Lal AA; Udhayakumar V; Todd CW
    Clin Vaccine Immunol; 2008 Nov; 15(11):1674-83. PubMed ID: 18784343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of adjuvants in inducing immune responses to different epitopes included in a multiepitope, multivalent, multistage Plasmodium falciparum candidate vaccine (FALVAC-1) in outbred mice.
    Rafi-Janajreh A; Tongren JE; Kensil C; Hackett C; Candal F; Lal A; Udhayakumar V
    Exp Parasitol; 2002 May; 101(1):3-12. PubMed ID: 12243733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
    Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum.
    Teo WH; Nurul AA; Norazmi MN
    Trop Biomed; 2012 Jun; 29(2):239-53. PubMed ID: 22735846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of pilot scale production process and characterization of a recombinant multiepitope malarial vaccine candidate FALVAC-1A expressed in Escherichia coli.
    Ravi G; Ella K; Lakshmi Narasu M
    Protein Expr Purif; 2008 Sep; 61(1):57-64. PubMed ID: 18619853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response.
    Lalitha PV; Ware LA; Barbosa A; Dutta S; Moch JK; Haynes JD; Fileta BB; White CE; Lanar DE
    Infect Immun; 2004 Aug; 72(8):4464-70. PubMed ID: 15271904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant multi-epitope, multi-stage malaria vaccine candidate expressed in Escherichia coli.
    Li M; Bi H; Dong W; Xu W; Li Q; Li Y
    Chin Med J (Engl); 1999 Aug; 112(8):691-7. PubMed ID: 11601273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rice-produced MSP142 of Plasmodium falciparum elicits antibodies that inhibit parasite growth in vitro.
    Chen Q; Liang W; Qian F; Qian B; Cao J; Zhang D; Xu Y; Tang L
    Parasite Immunol; 2016 Oct; 38(10):635-41. PubMed ID: 27493141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine.
    Shi YP; Hasnain SE; Sacci JB; Holloway BP; Fujioka H; Kumar N; Wohlhueter R; Hoffman SL; Collins WE; Lal AA
    Proc Natl Acad Sci U S A; 1999 Feb; 96(4):1615-20. PubMed ID: 9990073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenicity of a Bacterially Expressed Triple Chimeric Antigen of Plasmodium falciparum AARP, MSP-311 and MSP-119: PfAMSP-Fu35.
    Kalra A; Edula JR; Gupta PK; Pandey AK; Chauhan VS
    PLoS One; 2016; 11(10):e0165720. PubMed ID: 27798691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2.
    Wizel B; Houghten RA; Parker KC; Coligan JE; Church P; Gordon DM; Ballou WR; Hoffman SL
    J Exp Med; 1995 Nov; 182(5):1435-45. PubMed ID: 7595214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant protein vaccines against the asexual blood stages of Plasmodium falciparum.
    Anders RF; Adda CG; Foley M; Norton RS
    Hum Vaccin; 2010 Jan; 6(1):39-53. PubMed ID: 20061790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The stage-specific in vitro efficacy of a malaria antigen cocktail provides valuable insights into the development of effective multi-stage vaccines.
    Spiegel H; Boes A; Kastilan R; Kapelski S; Edgue G; Beiss V; Chubodova I; Scheuermayer M; Pradel G; Schillberg S; Reimann A; Fischer R
    Biotechnol J; 2015 Oct; 10(10):1651-9. PubMed ID: 25913888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
    Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
    Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
    Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.